(Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once ...

Co announces positive results from Trial CL-06, the first of two Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a once-a-day antibiotic, for the treatment ...

Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Rate for Biaxin(R), a Current Standard of Care Treatment Trial CL-05 and Trial CL-06 to Form the ...

Co announces Cethromycin at 300 mg once daily for seven days was well tolerated by subjects with hepatic impairment and subjects with normal hepatic function. The results suggest that no dose ...

(Nasdaq: ADLS), today announced positive results from TrialCL07-001, a thorough QT study of the Company's novel once-a-day oralantibiotic, cethromycin. This study was conducted to evaluate the ...

The antibiotic, cethromycin, also has shown in test tube experiments that it can fight MRSA, the so-called superbug staph infection that has caused worries because of its drug resistance.

to rise by 8 percent Wednesday. The drug, Cethromycin, likely will move toward regulatory approval later this year, the Woodridge-based company said. The primary market for anthrax-fighting drugs ...

Ketek is the first of the ketolide class of antibiotics to reach the market. Its closest competitor is cethromycin, which is being developed by tiny Advanced Life Sciences expects to present ...

Advanced Life Sciences Holdings Announces Cethromycin Granted FDA Orphan Drug Designation for Anthrax WOODRIDGE, Ill., March 14, 2007 -- Advanced Life Sciences Holdings, Inc. today announced that ...

Cethromycin is in late-stage evaluation as a treatment for respiratory tract infections. The NIAID plans to evaluate Advanced Life Sciences Holdings’ antibiotic, cethromycin, as a treatment for ...

Learn More After positive data in an anthrax study, the company's potential antibiotic cethromycin has been granted FDA Orphan Drug status for this indication. Advanced Life Sciences (NASDAQ ...

Advanced Life Sciences Holdings and Wyeth today said they signed a contract to develop and sell the antibiotic cethromycin in the Asia Pacific region, excluding Japan. Under the deal, Wyeth bought ...